Aproximación terapéutica a la enfermedad pulmonar obstructiva crónica (epoc)




descargar 277.11 Kb.
títuloAproximación terapéutica a la enfermedad pulmonar obstructiva crónica (epoc)
página6/6
fecha de publicación16.01.2016
tamaño277.11 Kb.
tipoDocumentos
med.se-todo.com > Documentos > Documentos
1   2   3   4   5   6
Cochrane Airways Group Cochrane Database of Systematic Reviews 2006; Volume 4.

  • Donohue JF, van Noord JA, Bateman ED, et al. A 6-month, placebo-controlled study comparing luna function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002;122:47-55.

  • Brusasco V, Hodder R, Miratvilles M, et al. Health outcomes following treatment for six months with once daily salmeterol in patients with COPD. Thorax 2003;58:399-404.

  • Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002;19:217-24.

  • van Noord JA, Bantje TA, Eland ME, et al. A randomized controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease: the Dutch Tiotropium Study Group. Thorax 2000;55:289-94.

  • Ram FSF, Jones PW, Castro AA, et al. Oral theophylline for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2006; Volume 4.

  • COMBIVENT Inhalation Aerosol Study Group. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. Chest 1994;105:1411-9.

  • COMBIVENT Inhalation Solution Study Group. Routine nebulized ipratropium and albuterol together are better than either alone in COPD. Chest 1997;112:1514-21.

  • Bourbeau J, Rouleau MY, Boucher S. Randomised controlled trial of inhaled corticosteroids in patients with chronic obstructive pulmonary disease. Thorax 1998;53:477-82.

  • Vestbo J, Sorensen T, Lange P, et al. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial (CCLS). Lancet 1999;353:1819-23.

  • Paggiaro PL, Dahle R, Bakran I, et al. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease: International COPD Study Group. Lancet 1998;351:773-80.

  • Burge PS, Calverley PM, Jones PW, et al. Randomised, double-blind, placebo-controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000;320:1297-1303.

  • Van der Valk P, Monninkhof E, van der Palen J, et al. Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study. Am J Respir Crit Care Med 2002;166:1358-63.

  • Sin DD, Wu L, Anderson JA, et al. Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease (ISEEC). Thorax 2005;60:992-7.

  • Calverley PMA, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease (TORCH). NEJM 2007;356:775-89.

  • Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. NEJM 2000;343:1902-9.

  • Pauwels RA, Lofdahl CG, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking: European Respiratory Society on Chronic Obstructive Pulmonary Disease (EUROSCOP). NEJM 1999;340:1948-53.

  • Mahler DA, Wire P, Horstman D, et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002;166:1084-91.

  • Szafranski W, Cukier A, Ramirez A, et al. Efficay and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003;21:74-81.

  • Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial (TRISTAN). Lancet 2003;361:449-56.

  • Nannini L, Cates CJ, Lasserson TJ, Poole P. Combined corticosteroid and longacting beta-agonist in one inhaler for chronic obstructive pulmonary disease. Cochrane Database for Systematic Reviews 2006, Volume 4.

  • Hanania NA, Darken P, Horstman D, Reisner C, Lee B, Davis S, et al. The efficacy and safety of fluticasone propionate (250 micro g)/salmeterol (50 micro g) combined in the diskus inhaler for the treatment of COPD. Chest 2003;124:834-43.

  • Calverly PM, Bonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. European Respiratory Journal 2003;22:912-9.

  • Walters JAE, Walters EH, Wood-Baker R. Oral corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database for Systematic Reviews 2006, Volume 4.

  • Decramer M, Rutten-van Molken M, Dekhuijzen PN, et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet 2005;365:1552-60.

  • Brown CD, McCrory D, White J. Inhaled short-acting beta2-agonists versus ipratropium for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database for Systematic Reviews 2006, Volume 4.

  • McCrory DC, Brown CD. Anticholinergic bronchodilators versus beta2-sympathomimetic agents for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database for Systematic Reviews 2006, Volume 4.

  • Wood Baker RR, Gibson PG, Hannay M, et al. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database for Systematic Reviews 2006, Volume 4.

  • Barr RG, Rowe BH, Camargo CA Jr. Methylxanthines for exacerbations of chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2006; Volume 4.

  • Álvarez-Sala JL, Cimas E, Masa JF, et al. Recomendaciones para la atención al paciente con enfermedad pulmonar obstructiva crónica. Arch Bronconeumol 2001;37:269-78.






  • 1   2   3   4   5   6

    similar:

    Aproximación terapéutica a la enfermedad pulmonar obstructiva crónica (epoc) iconEl tabaquismo, es causa de muchas patologías. Entre ellas un 90%...

    Aproximación terapéutica a la enfermedad pulmonar obstructiva crónica (epoc) iconEl tromboembolismo pulmonar es una enfermedad frecuente y potencialmente...

    Aproximación terapéutica a la enfermedad pulmonar obstructiva crónica (epoc) iconE) Enfermedad de inflamatoria crónica de las vías aéreas, en la cual...

    Aproximación terapéutica a la enfermedad pulmonar obstructiva crónica (epoc) iconEs una enfermedad crónica que se caracteriza por un aumento de la...

    Aproximación terapéutica a la enfermedad pulmonar obstructiva crónica (epoc) iconLa enfermedad renal crónica (erc) es una de las enfermedades renales...

    Aproximación terapéutica a la enfermedad pulmonar obstructiva crónica (epoc) iconAula 1 Química. Campus Libertad. Av Libertad 5470. Corrientes
    «sin carga», entendiéndose por carga un impuesto, ley o enfermedad. Se dice que aquellos individuos que no sucumben ante la enfermedad...

    Aproximación terapéutica a la enfermedad pulmonar obstructiva crónica (epoc) iconEnfisema pulmonar

    Aproximación terapéutica a la enfermedad pulmonar obstructiva crónica (epoc) iconLa eficacia del intercambio pulmonar de gases depende de

    Aproximación terapéutica a la enfermedad pulmonar obstructiva crónica (epoc) iconDifusión de O2 desde los alvéolos a la sangre capilar pulmonar

    Aproximación terapéutica a la enfermedad pulmonar obstructiva crónica (epoc) iconAproximación a la historia etnográfica


    Medicina



    Todos los derechos reservados. Copyright © 2015
    contactos
    med.se-todo.com